Helen Gieser
CEO and Chair of the Management Board
Replay available
Fresenius Medical Care AG (NYSE: FMS) Q3 2025 earnings conference call, held 2025-11-04. Replay captured from the company's public earnings webcast.

CEO and Chair of the Management Board
Chief Financial Officer
Analyst, ODDO BHF
Ladies and gentlemen, welcome to the report on the third quarter 2025 conference call. I am Sandra, the chorus call operator. I would like to remind you that all participants have been listed in only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Dominic Hager. Please go ahead, sir. Thank you, Sandra. Welcome, everyone, to our earnings call for the third quarter 2025. As always, I start out the call by mentioning our cautionary language that is in our safe harbor statement as well as in our presentation and in all the materials that we have distributed earlier today. For further details concerning risks and uncertainties, please refer to these documents and to our SEC filings. We will have roughly one hour for the call. In order to give everyone the chance to ask questions, we would limit the number of questions to two. Thank you for making this work, as always. Let me now welcome Helen Gieser, CEO and Chair of the Management Board, and Martin Fischer, our Chief Financial Officer. Helen, the floor is yours. Thank you, Dominic. I'd also like to extend a warm welcome to everyone on the call. Thank you for taking the time to join us today and your continued interest in Fresenius Medical Care. As many of you know, the U.S. is in government shutdown since the 1st of October, and many healthcare policy decisions are open. like the questions of extended tax subsidies for the exchanges and whether they will expire by the end of this year, or the publication of final 2026 ESRD PPS ...